



Patent
Attorney's Docket No. 017753-154

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of

Thérèse de BIZEMONT *et al.*

Application No.: 09/836,439

Filed: April 17, 2001

For: **GENE THERAPY WITH CHIMERIC
OLIGONUCLEOTIDES DELIVERED
BY A METHOD COMPRISING A
STEP OF IONTOPHORESIS**

)
)
) Group Art Unit: 3763

)
) Examiner: Unassigned
)
)
)
)
)
)

#5

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

U.S. Patent No. 5,374,242

U.S. Patent No. 5,250,022

T. Asahara *et al.*, "Japanese Ophthalmological Society," Vol. 45, pp. 31-39 (2001)

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: November 28, 2001